MarketCap
Facebook
X
Telegram
Omnicell Balance Sheet 2025-2008 | OMCL
Brief overview of Omnicell's balance sheet structure
The comparison uses five available annual reports from the 2021–2025 interval.
Across five reporting periods, assets decreased -7.8%, from $2.1 billion to $2 billion, producing a negative trend.
Liability growth of -25.4% trailed asset growth of -7.8%. The funding structure became more resilient.
Equity accounts for 62.4% of assets. Against the initial 53.5%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$159.8 million. The balance sheet therefore carries a net cash position.
Cash equals 10% of the balance sheet, compared with 16.3% five periods ago. This is the readily available cushion.
Retained earnings reached $384.9 million, changing +4.4% over the period. A positive accumulated result supports equity.
Conclusion
Omnicell has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Omnicell
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-160 M | -327 M | -424 M | -280 M | -296 M | -6.53 M | -16.5 M | 68.2 M | 178 M | 200 M | -82.2 M | -126 M | -105 M | -62.3 M | -192 M | - | - | - |
Long Term Debt |
24.8 M | 31.1 M | 33.9 M | 39.4 M | 39.9 M | 467 M | 50 M | 135 M | 195 M | 246 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
12 M | 10.7 M | 10.5 M | 10.8 M | 12.9 M | 12.2 M | 10.1 M | - | 15.2 M | 8.41 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 159 M | 197 M | 251 M | 323 M | 51.7 M | 57.8 M | 51.1 M | 51.2 M | 20.3 M | - | - | - |
Total Current Liabilities |
477 M | 596 M | 368 M | 428 M | 876 M | 276 M | 237 M | 205 M | 213 M | 181 M | 125 M | 112 M | 92.4 M | 83.1 M | 58.9 M | 58.2 M | - | - |
Total Liabilities |
743 M | 878 M | 1.04 B | 1.08 B | 996 M | 857 M | 396 M | 402 M | 463 M | 503 M | 176 M | 170 M | 144 M | 134 M | 79.2 M | 78 M | - | - |
Deferred Revenue |
172 M | 141 M | 122 M | 119 M | 112 M | 125 M | 94.9 M | 90.8 M | 93.9 M | 94.5 M | 62 M | 58.6 M | 47.6 M | 44 M | 33.4 M | - | - | - |
Retained Earnings |
385 M | 383 M | 370 M | 391 M | 369 M | 291 M | 259 M | 197 M | 123 M | 100 M | 99.8 M | 69 M | 38.5 M | 14.5 M | -1.64 M | -12 M | - | - |
Total Assets |
1.97 B | 2.12 B | 2.23 B | 2.21 B | 2.14 B | 1.82 B | 1.24 B | 1.08 B | 980 M | 935 M | 579 M | 560 M | 493 M | 442 M | 362 M | 343 M | - | - |
Cash and Cash Equivalents |
197 M | 369 M | 468 M | 330 M | 349 M | 486 M | 127 M | 67.2 M | 32.4 M | 54.5 M | 82.2 M | 126 M | 105 M | 62.3 M | 192 M | 176 M | 169 M | 120 M |
Book Value |
1.23 B | 1.24 B | 1.19 B | 1.13 B | 1.15 B | 968 M | 845 M | 680 M | 517 M | 432 M | 402 M | 390 M | 349 M | 308 M | 283 M | 265 M | - | - |
Total Shareholders Equity |
1.23 B | 1.24 B | 1.19 B | 1.13 B | 1.15 B | 968 M | 845 M | 680 M | 554 M | 459 M | 402 M | 390 M | 349 M | 308 M | 283 M | 265 M | 242 M | 234 M |
All numbers in USD currency
Quarterly Balance Sheet Omnicell
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
20.3 M | 22.7 M | 27.6 M | 30.8 M | 33 M | 31.1 M | 31.5 M | 33.7 M | 34.6 M | 33.9 M | 32.8 M | 35.5 M | 36.9 M | 39.4 M | 41.9 M | 43.4 M | 37.3 M | 39.9 M | 40.4 M | 42.5 M | 45.4 M | 48.9 M | 48.9 M | - | - | 50 M | 77.1 M | 76.6 M | 50 M | 135 M | 135 M | 135 M | 135 M | 195 M | 195 M | 195 M | 195 M | 246 M | 246 M | 246 M | 246 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
707 M | 747 M | 728 M | 882 M | 894 M | 878 M | 1.07 B | 1.09 B | 1.1 B | 1.04 B | 1.03 B | 1.03 B | 1.11 B | 1.08 B | 1.04 B | 1.04 B | 1.05 B | 996 M | 940 M | 908 M | 876 M | 857 M | 857 M | 857 M | 857 M | 396 M | 396 M | 396 M | 396 M | 402 M | 402 M | 402 M | 402 M | 462 M | 462 M | 462 M | 462 M | 503 M | 503 M | 503 M | 503 M | 176 M | 176 M | 176 M | 176 M | 170 M | 170 M | 170 M | 170 M | 144 M | 144 M | 144 M | 144 M | 134 M | 134 M | 134 M | 134 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M |
Deferred Revenue |
188 M | 212 M | 179 M | 154 M | 160 M | 141 M | 152 M | 150 M | 165 M | 122 M | 125 M | 125 M | 143 M | 119 M | 114 M | 109 M | 128 M | 112 M | 115 M | 121 M | 120 M | 100 M | 100 M | 100 M | 100 M | 90.9 M | 90.9 M | 90.9 M | 90.9 M | 81.8 M | 81.8 M | 81.8 M | 81.8 M | 86.1 M | 78.8 M | 78.8 M | - | 87.5 M | - | - | - | 53.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
421 M | 396 M | 387 M | 382 M | 376 M | 383 M | 367 M | 358 M | 355 M | 370 M | 385 M | 379 M | 376 M | 391 M | 419 M | 402 M | 393 M | 369 M | 355 M | 325 M | 305 M | 291 M | 291 M | 291 M | 291 M | 259 M | 259 M | 259 M | 259 M | 197 M | 197 M | 197 M | 197 M | 160 M | 160 M | 160 M | 160 M | 100 M | 100 M | 100 M | 100 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 69 M | 69 M | 69 M | 69 M | 38.5 M | - | - | - | 14.5 M | - | - | - | -1.64 M | - | - | - |
Total Assets |
2 B | 2 B | 1.95 B | 2.15 B | 2.15 B | 2.12 B | 2.3 B | 2.29 B | 2.28 B | 2.23 B | 2.22 B | 2.19 B | 2.25 B | 2.21 B | 2.18 B | 2.13 B | 2.12 B | 2.14 B | 2.05 B | 1.96 B | 1.89 B | 1.82 B | 1.82 B | 1.82 B | 1.82 B | 1.24 B | 1.24 B | 1.24 B | 1.24 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 935 M | 935 M | 935 M | 935 M | 579 M | 579 M | 579 M | 579 M | 560 M | 560 M | 560 M | 560 M | 493 M | 493 M | 493 M | 493 M | 442 M | 442 M | 442 M | 442 M | 364 M | 364 M | 364 M | 364 M |
Cash and Cash Equivalents |
292 M | 239 M | 180 M | 399 M | 387 M | 369 M | 571 M | 557 M | 512 M | 468 M | 447 M | 399 M | 340 M | 330 M | 266 M | 245 M | 265 M | 349 M | 482 M | 614 M | 548 M | 490 M | 486 M | 486 M | 486 M | 127 M | 127 M | 127 M | 127 M | 67.2 M | 67.2 M | 67.2 M | 67.2 M | 32.4 M | 32.4 M | 32.4 M | 32.4 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 126 M | 126 M | 126 M | 126 M | 105 M | 105 M | 105 M | 105 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 192 M | 192 M | 192 M | 192 M |
Book Value |
1.29 B | 1.26 B | 1.22 B | 1.26 B | 1.26 B | 1.24 B | 1.23 B | 1.2 B | 1.19 B | 1.19 B | 1.19 B | 1.16 B | 1.14 B | 1.13 B | 1.14 B | 1.09 B | 1.07 B | 1.15 B | 1.11 B | 1.05 B | 1.01 B | 968 M | 968 M | 968 M | 968 M | 845 M | 845 M | 845 M | 845 M | 680 M | 680 M | 680 M | 680 M | 554 M | 554 M | 554 M | 554 M | 432 M | 432 M | 432 M | 432 M | 402 M | 402 M | 402 M | 402 M | 390 M | 390 M | 390 M | 390 M | 349 M | 349 M | 349 M | 349 M | 308 M | 308 M | 308 M | 308 M | 283 M | 283 M | 283 M | 283 M |
Total Shareholders Equity |
1.29 B | 1.26 B | 1.22 B | 1.26 B | 1.26 B | 1.24 B | 1.23 B | 1.2 B | 1.19 B | 1.19 B | 1.19 B | 1.16 B | 1.14 B | 1.13 B | 1.14 B | 1.09 B | 1.07 B | 1.15 B | 1.11 B | 1.05 B | 1.01 B | 968 M | 968 M | 968 M | 968 M | 845 M | 845 M | 845 M | 845 M | 680 M | 680 M | 680 M | 680 M | 554 M | 554 M | 554 M | 554 M | 459 M | 432 M | 432 M | 432 M | 420 M | 402 M | 402 M | 402 M | 390 M | 390 M | 390 M | 390 M | 349 M | 349 M | 349 M | 349 M | 308 M | 308 M | 308 M | 308 M | 283 M | 283 M | 283 M | 283 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Omnicell, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Teladoc Health
TDOC
|
$ 6.26 | 0.24 % | $ 1.1 B |  USA |
 |
10x Genomics
TXG
|
$ 65.6 | 4.71 % | $ 8.18 B | USA |
 |
Veeva Systems
VEEV
|
$ 264.84 | 1.3 % | $ 43.3 B | USA |
 |
Zhongchao
ZCMD
|
$ 0.85 | 0.29 % | $ 2.91 M |  China |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
American Well Corporation
AMWL
|
$ 13.34 | 2.69 % | $ 214 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
$ 4.22 | 1.41 % | $ 482 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.52 | 1.15 % | $ 1.25 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.7 | 0.59 % | $ 119 M | USA |
 |
HealthEquity
HQY
|
$ 93.36 | 0.24 % | $ 8.04 B | USA |
 |
HealthStream
HSTM
|
$ 28.72 | 1.78 % | $ 862 M | USA |
 |
So-Young International
SY
|
$ 2.65 | 0.18 % | $ 206 M | China |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.6 | 1.74 % | $ 141 M | USA |
 |
Progyny
PGNY
|
$ 27.15 | 4.66 % | $ 2.31 B | USA |
 |
Phreesia
PHR
|
$ 10.22 | 0.76 % | $ 611 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
$ 20.03 | 0.2 % | $ 1.47 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |